MAD2L2 and cancer: More specifically, they reported that REV-7 inactivation led to increased chemosensitivity to cisplatin and doxorubicin, by promoting DSB accumulation and apoptotic pathways, while it also recovered chemosensitivity in cisplatin-resistant cancer cells.